42832-87-1

Usage

Uses

Used in Organic Synthesis:
3,6-Diamino-9(10)-acridone is used as a key intermediate for the synthesis of various organic compounds. Its application in this field is due to its ability to participate in a range of chemical reactions, such as condensation, substitution, and addition reactions, which are essential for creating complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,6-diamino-9(10)-acridone is used as a building block for the development of new drugs. Its unique chemical structure allows it to be modified and functionalized to create potential therapeutic agents with specific biological activities.
Used in Dye Manufacturing:
3,6-Diamino-9(10)-acridone is also utilized in the manufacturing of dyes, particularly those used in the textile and printing industries. Its light brown solid form can be processed and combined with other chemicals to produce a wide range of colors and shades.
Used in Research and Development:
Due to its versatile chemical properties, 3,6-diamino-9(10)-acridone is often employed in research and development laboratories. Scientists and researchers use 3,6-diamino-9(10)-acridone to study various chemical reactions, explore new synthetic pathways, and develop innovative applications in different industries.

Upstream product

• 96461-20-0 3-amino-6-nitro-10H-acridin-9-one 
• 857549-96-3 4-acetylamino-2-(3-amino-anilino)-benzoic acid 
• 101-81-5 Diphenylmethane 
• 861306-84-5 2,4,2',4'-tetraamino-benzophenone 
• 102-28-3 m-acetamide aniline 
• 728899-93-2 2-(3-amino-anilino)-4-nitro-benzoic acid 
• 38667-55-9 4-Acetylamino-2-chlorobenzoic acid 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 1817-76-1 2,2',4,4'-tetranitrodiphenylmethane 
• 71535-97-2 2,2',4,4'–tetranitrodibenzophenone 
• 99-09-2 3-nitro-aniline 
• 122-28-1 N-(3-nitrophenyl)acetanilide 
• 95-74-9 3-chloro-p-toluidine 
• 7149-79-3 N-(3-chloro-4-methylphenyl)acetamide 

Downstream Products

• 92-62-6 proflavine 
• 1026744-60-4 N-{6-Acetylamino-9-[4-(piperidine-1-sulfonyl)-phenylamino]-acridin-3-yl}-acetamide 
• 1027173-67-6 N-[6-Acetylamino-9-(4-dimethylsulfamoyl-phenylamino)-acridin-3-yl]-acetamide 
• 1026325-19-8 N-[6-Acetylamino-9-(4-methoxy-phenylamino)-acridin-3-yl]-acetamide 
• 1027251-28-0 N-[6-Acetylamino-9-(4-hydroxy-phenylamino)-acridin-3-yl]-acetamide 
• 155457-49-1 N-(6-Acetylamino-9-p-tolylamino-acridin-3-yl)-acetamide 
• 1026723-36-3 N-(6-Acetylamino-9-phenylamino-acridin-3-yl)-acetamide 
• 80257-99-4 N-[6-Acetylamino-9-(4-methanesulfonylamino-2-methoxy-phenylamino)-acridin-3-yl]-acetamide 
• 166405-61-4 9-phenyl-3,6-bis<(ethoxycarbonyl)amino>acridine 
• 58067-04-2 9-phenyl-acridine-3,6-diamine 

Relevant academic research and scientific papers

Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity

A series of new 3,6,9-trisubstituted acridine derivatives with fluorine substituents on phenyl ring were synthesized and their interaction with calf thymus DNA was investigated. Analysis using UV–Vis absorbance spectra provided valuable information about

Antiprotozoal activity and DNA binding of dicationic acridones

Dicationic acridone derivatives were synthesized and their antiparasitic activity was evaluated. Acridones displayed in vitro nanomolar IC50 values against Trypanosoma brucei rhodesiense STIB900 with selectivity indices >1000. Compounds 1b, 3a,

Novel trisubstituted acridines as human telomeric quadruplex binding ligands

A novel series of trisubstituted acridines were synthesized with the aim of mimicking the effects of BRACO19. These compounds were synthesized by modifying the molecular structure of BRACO19 at positions 3 and 6 with heteroacyclic moieties. All of the derivatives presented in the study exhibited stabilizing effects on the human telomeric DNA quadruplex. UV-vis spectroscopy, circular dichroism, linear dichroism and viscosimetry were used in order to study the nature of the DNA binding in more detail. The results show that all of the novel derivatives were able to fold the single-stranded DNA sequences into antiparallel G-quadruplex structures, with derivative 15 exhibiting the highest stabilizing capability. Cell cycle analysis revealed that a primary trend of the "braco"-like derivatives was to arrest the cells in the S- and G 2M-phases of the cell cycle within the first 72 h, with derivative 13 and BRACO19 proving particularly effective in suppressing cell proliferation. All studies derivatives were less toxic to human fibroblast cell line in comparison with HT 29 cancer cell line.

Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents

The design, synthesis, biophysical and biochemical evaluation is presented of a new series of benzylamino-substituted acridines as G-quadruplex binding telomerase inhibitors. Replacement of the previously reported anilino substituents by benzylamino group

CANCER TREATMENT USING SPECIFIC 3,6,9-SUBSTITUTED ACRIDINES

The present invention relates to a 3,6,9 acridine compound and optionally substituted derivatives thereof that may be useful in the treatment of cancer. The invention also provides compositions comprising the compounds and uses thereof.

Therapeutic acridone and acridine compounds

The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is

Novel acridine-triazenes as prototype combilexins: Synthesis, DNA binding, and biological activity

A series of bifunctional ligands has been developed as prototype DNA- binding combilexins using a DNA template-directed approach. These novel agents contain a 1,3-diaryltriazene linker moiety, present in the established DNA minor groove-binder berenil [1,3-bis(4'-amidinophenyl)-triazene], which is attached to an intercalating acridine chromophore by a functionalized thiazole residue. This 9-arylacridine is predicted to confer rotational freedom to the hybrid molecule and thus facilitate bifunctional interaction with double-stranded DNA through a combination of 'classical' intercalation and minor groove-binding processes. The noncovalent DNA-binding properties of these acridine-triazene combilexins, together with the component molecular fragments, have been examined by fluorescence quenching and thermal denaturation studies with calf thymus DNA and two oligonucleotides, [poly(dA- dT)]2 and [poly(dG-dC)]2. In addition, the binding behaviors of these acridine compounds are compared to those of proflavine (3,6-diaminoacridine) and its 9-phenyl derivative. The results indicate that the hybrid agents (i) are more DNA-affinic than either molecular component, (ii) retain the AT- preferential binding properties of the parent difunctionalized 1,3- diaryltriazene residues, despite weak GC-preferential behavior associated with the acridine chromophore, and (iii) have a reduced binding affinity at pH 7 that reflects the protonation status of the acridine. In contrast, the more basic proflavines show much greater binding affinity and a marked preference for GC-rich DNA sequences. In vitro cytotoxicity data with L1210 mouse leukemia and A2780 human colon cancer cell lines show that the conjugate molecules are ~10-40-fold more potent than the acridine or triazene subunits and have activities that compare favorably with those of other reported synthetic combilexins. Intercalative binding modes with a model d(GATACGATAC)·d(GTATCGTATC) target duplex have been investigated using molecular modeling techniques. These studies provide a rational basis for the binding properties and suggest that the prototype combilexins can bind in a bimodal manner that induces little distortion of the host DNA duplex. Energy- minimized models for the possible dual interactions are discussed.